Company News-Bio-Thera Solutions, Ltd.

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

03-062023

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8010, an Antibody Drug Conjugate Targeting HER2 for the Treatment of Advanced Solid Tumors

Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, to...
01-162023

China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra® (Tocilizumab)

World’s First Approved Biosimilar toActemra® Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), ...
12-022022

Bio-Thera Solutions Announces Presentation of BAT8009 (B7-H3-ADC) at the 2nd Annual ADC Target Selection Summit

Guangzhou, China --(BUSINESS WIRE)--Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing apipeli...